Alzheimer's disease, the hippocampus and neuroimaging;Maladie d'Alzheimer, hippocampe et neuroimagerie

Encephale

Volumn 32, Issue 6 C4, 2006, Pages

  Mevel, K ^a   Chetelat, G ^a   Desgranges, B ^a   Eustache, F ^b  

^a UNIVERSITÉ DE CAEN   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AUTOPSY; BRAIN METABOLISM; COGNITION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HIPPOCAMPUS; HUMAN; NEUROANATOMY; NEUROBIOLOGY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW;

EID: 33846195081     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0013-7006(06)76306-0     Document Type: Review

References (66)

1. AMERICAN PSYCHIATRIC ASSOCIATION. DSM IV : Diagnostic and Statistical Manual of Mental Disorders (4th ed). Washington : American Psychiatric Association Press, 1994.
2. ARNAIZ E, JELIC V, ALMKVIST O et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001 ; 12 : 851-5.
3. BARON JC, CHÉTELAT G, DESGRANGES B et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage 2001 ; 14 : 298-309.
4. BRAAK H, BRAAK E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991 ; 82 : 239-59.
5. BRAAK H, BRAAK E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand 1996 (Suppl 165) : 3-12.
6. BRAAK H, BRAAK E, BOHL J. Staging of Alzheimer-related cortical destruction. Eur Neurol 1993 ; 33 : 403-8.
7. BRADLEY KM, O'SULLIVAN VT, SOPER ND et al. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain 2002 ; 125 : 1772-81.
8. CALLEN DJ, BLACK SE, CALDWELL CB. Limbic system perfusion in Alzheimer's disease measured by MRI-coregistered HMPAO SPET. Eur J Nucl Med Mol Imaging 2002 ; 29 : 899-906.
9. CHÉTELAT G, BARON JC. Early diagnosis of Alzheimer's disease : contribution of structural neuroimaging. Neuroimage 2003 ; 18 : 525-41.
10. CHÉTELAT G, DESGRANGES B, DE LA SAYETTE V et al. Aux frontières de la maladie d'Alzheimer. Rev Neurol, Paris, 2004 ; 160 : 2S55-2S63.
11. CHÉTELAT G, DESGRANGES B, DE LA SAYETTE V et al. Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain 2003a ; 126 : 1955-67.
12. CHÉTELAT G, DESGRANGES B, DE LA SAYETTE V et al. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport 2002 ; 13 : 1939-43.
13. CHÉTELAT G, DESGRANGES B, DE LA SAYETTE V et al. Mild cognitive impairment : Can FDG-PET predict who is to rapidly convert to Alzheimer's disease ? Neurology 2003b ; 60 : 1374-7.
14. DE LA MONTE SM. Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease. Ann Neurol 1989 ; 25 : 450-9.
15. DE SANTI S, DE LEON MJ, RUSINEK H et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001 ; 22 : 529-39.
16. DE TOLEDO-MORRELL L, GONCHAROVA I, DICKERSON B et al. From healthy aging to early Alzheimer's disease : in vivo detection of entorhinal cortex atrophy. Ann NY Acad Sci 2000 ; 911 : 240-53.
17. DELACOURTE A, DAVID JP, SERGEANT N et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999 ; 52 : 1158-65.
18. DESGRANGES B, EUSTACHE F. Maladie d'Alzheimer et imagerie fonctionnelle : mieux comprendre la physiopathologie. Neurologies 2004b ; 66 : 534-9.
19. DESGRANGES B, BARON JC, EUSTACHE F. The functional neuroanatomy of episodic memory : the role of the frontal lobes, the hippocampal formation, and other areas. Neuroimage 1998b ; 8 : 198-213.
20. DESGRANGES B, BARON JC, DE LA SAYETTE V et al. The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain 1998a ; 121 : 611-31.
21. DESGRANGES B, BARON JC, LALEVÉE C et al. The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET : relationship to degree of deterioration. Brain 2002 ; 125 : 1116-24.
22. DESGRANGES B, BERNARD F, EUSTACHE F. La distinction épisodique/ sémantique et l'organisation catégorielle de la mémoire sémantique : données de l'imagerie cérébrale fonctionnelle. Rev Neuropsychol 2003 ; 1 : 115-62.
23. DESGRANGES B, CHÉTELAT G, EUSTACHE F. Les substrats cérébraux des troubles de la mémoire épisodique dans la maladie d'Alzheimer. Rev Neurol Paris, 2004a ; 160 : 2S44-2S54.
24. DRZEZGA A, LAUTENSCHLAGER N, SIEBNER H et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease : a PET follow-up study. Eur J Nucl Med Mol Imaging 2003 ; 30 : 1104-13.
25. ELGH E, SUNDSTROM T, NASMAN B et al. Memory functions and rCBF (99m)Tc-HMPAO SPET : developing diagnostics in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2002 ; 29 : 1140-8.
26. EUSTACHE F, DESGRANGES B, GIFFARD B et al. Entorhinal cortex disruption causes memory deficit in early Alzheimer's disease as shown by PET. Neuroreport 2001 ; 12 : 683-5.
27. GARRIDO GE, FURUIE SS, BUCHPIGUEL CA et al. Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer's disease : a combined MRI and SPECT study. J Neurol Neurosurg Psychiatry 2002 ; 73 : 508-16.
28. GEDDES JW, MONAGHAN DT, COTMAN CW et al. Plasticity of hippocampal circuitry in Alzheimer's disease. Science 1985 ; 230 : 1179-81.
29. HERHOLZ K, SALMON E, PERANI D et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002 ; 17 : 302-16.
30. HIRONO N, HASHIMOTO M, YASUDA M et al. The effect of APOE epsilon4 allele on cerebral glucose metabolism in AD is a function of age at onset. Neurology 2002 ; 58 : 743-50.
31. IBANEZ V, PIETRINI P, ALEXANDER GE et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998 ; 50 : 1585-93.
32. ISHII K, SASAKI M, YAMAJI S et al. Paradoxical hippocampus perfusion in mild-to-moderate Alzheimer's disease. J Nucl Med 1998a ; 39 : 293-8.
33. ISHII K, SASAKI M, YAMAJI S et al. Relatively preserved hippocampal glucose metabolism in mild Alzheimer's disease. Dement Geriatr Cogn Disord 1998b ; 9 : 317-22.
34. ISHII K, WILLOCH F, MINOSHIMA S et al. Statistical brain mapping of 18F-FDG PET in Alzheimer's disease : validation of anatomic standardization for atrophied brains. J Nucl Med 2001 ; 42 : 548-57.
35. JIN K, PEEL AL, MAO XO et al. Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci USA 2004 ; 101 : 343-7.
36. JOBST KA, SMITH AD, SZATMARI M et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet, 1992 ; 340 : 1179-83.
37. JOHNSON KA, JONES K, HOLMAN BL et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998 ; 50 : 1563-71.
38. JULIN P, LINDQVIST J, SVENSSON L et al. MRI-guided SPECT measurements of medial temporal lobe blood flow in Alzheimer's disease. J Nucl Med 1997 ; 38 : 914-9.
39. KALPOUZOS G, EUSTACHE F, VIADER F et al. Working memory and FDG-PET dissociate early and late onset Alzheimer disease patients. J Neurol 2005 ; 252 : 548-58.
40. KILLIANY RJ, GOMEZ-ISLA T, MOSS M et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 2000 ; 47 : 430-9.
41. KITAYAMA N, MATSUDA H, OHNISHI T et al. Measurements of both hippocampal blood flow and hippocampal gray matter volume in the same individuals with Alzheimer's disease. Nucl Med Commun 2001 ; 22 : 473-7.
42. KOGURE D, MATSUDA H, OHNISHI T et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med 2000 ; 41 : 1155-62.
43. LAAKSO MP, FRISONI GB, KONONEN M et al. Hippocampus and entorhinal cortex in frontotemporal dementia and Alzheimer's disease : a morphometric MRI study. Biol Psychiatry 2000 ; 47 : 1056-63.
44. MATSUDA H, KANETAKA H, OHNISHI T et al. Brain SPET abnormalities in Alzheimer's disease before and after atrophy correction. Eur J Nucl Med Mol Imaging 2002 ; 29 : 1502-5.
45. McKHANN G, DRACHMAN D, FOLSTEIN M et al. Clinical diagnosis of Alzheimer's disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 ; 34 : 939-44.
46. MINOSHIMA S, FOSTER NL, KUHL DE. Posterior cingulate cortex in Alzheimer's disease. Lancet 1994 ; 344 : 895.
47. MINOSHIMA S, GIORDANI B, BERENT S et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997 ; 42 : 85-94.
48. MOSCONI L, TSUI WH, DE SANTI S et al. Reduced hippocampal metabolism in MCI and AD : automated FDG-PET image analysis. Neurology 2005 ; 64 : 1860-7.
49. MURIALDO G, NOBILI F, ROLLERO A et al. Hippocampal perfusion and pituitary-adrenal axis in Alzheimer's disease. Neuropsychobiology 2000 ; 42 : 51-7.
50. NAGAHAMA Y, NABATAME H, OKINA T et al. Cerebral correlates of the progression rate of the cognitive decline in probable Alzheimer's disease. Eur Neurol 2003 ; 50 : 1-9.
51. NEBU A, IKEDA M, FUKUHARA R et al. Utility of (99m)Tc-HM-PAO SPECT hippocampal image to diagnose early stages of Alzheimer's disease using semiquantitative analysis. Dement Geriatr Cogn Disord 2001 ; 12 : 153-7.
52. NESTOR PJ, FRYER TD, IKEDA M et al. Retrosplenial cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease). Eur J Neurosci 2003b ; 18 : 2663-7.
53. NESTOR PJ, FRYER TD, SMIELEWSKI P et al. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 2003a ; 54 : 343-51.
54. OHNISHI T, HOSHI H, NAGAMACHI S et al. High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric diseases. J Nucl Med 1995 ; 36 : 1163-9.
55. PERANI D, BRESSI S, CAPPA SF et al. Evidence of multiple memory systems in the human brain. A [18F]FDG PET metabolic study. Brain 1993 ; 116 (4) : 903-19.
56. PETERSEN RC, DOODY R, KURZ A et al. Current concepts in mild cognitive impairment. Arch Neurol 2001 ; 58 : 1985-92.
57. PETERSEN RC, JACK CR Jr, XU YC et al. Memory and MRI-based hippocampal volumes in aging and AD. Neurology 2000 ; 54 : 581-7.
58. PETIT-TABOUÉ MC, LANDEAU B, DESSON JF et al. Effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping. Neuroimage 1988 ; 7 : 176-84.
59. REIMAN EM, CHEN K, ALEXANDER GE et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 2004 ; 101 : 284-9.
60. REMY F, MIRRASHED F, CAMPBELL B et al. Verbal episodic memory impairment in Alzheimer's disease : a combined structural and functional MRI study. Neuroimage 2005 ; 25 : 253-66.
61. RODRIGUEZ G, VITALI P, CALVINI P et al. Hippocampal perfusion in mild Alzheimer's disease. Psychiatry Res 2000 ; 100 : 65-74.
62. SCHEFF SW, SPARKS L, PRICE DA. Quantitative assessment of synaptic density in the entorhinal cortex in Alzheimer's disease. Ann Neurol 1993 ; 34 : 356-61.
63. SMITH AD. Imaging the progression of Alzheimer pathology through the brain. Proc Natl Acad Sci USA 2002 ; 99 : 4135-7.
64. TULVING E. Organization of memory : Quo vadis ? In : Gazzaniga MS, ed. The cognitive neurosciences. Cambridge : MIT Press, 1995 : 839-47.
65. VAN DER FLIER WM, VAN DEN HEUVEL DM, WEVERLINGRIJNSBURGER AW et al. Cognitive decline in AD and mild cognitive impairment is associated with global brain damage. Neurology 2002 ; 59 : 874-9.
66. YASUNO F, IMAMURA T, HIRONO N et al. Age at onset and regional cerebral glucose metabolism in Alzheimer's disease. Dement Geriatr Cogn Disord 1998 ; 9 : 63-7.